BRIEF—Phase III data for Barhemsys published in Anesthesiology

Following the publication of positive Phase III data for Barhemsys (amisulpride) in the journal Anesthesiology, Cambridge, UK-based Acacia Pharma has welcomed an accompanying editorial assessing the trial’s significance.

The editorial describes the study as “the first randomized placebo-controlled trial proving the effectiveness of a rescue treatment for postoperative nausea and vomiting after failed prophylaxis with a different agent.”

Acacia’s chief medical officer Gabriel Fox said: “We are honoured that a journal as prestigious as Anesthesiology has selected our trial with Barhemsys as the basis of an editorial.”

He added: “We agree with their observation that many millions of patients are suffering with PONV each year and that more research into effective treatments is urgently required. We remain fully committed to further investigation in this highly important and clinically relevant field.”